ID | 109939 |
Title Transcription | クリゾチニブ ガ ソウコウ シタ Performance Status フリョウ anaplastic lymphoma kinase イデンシ テンザ ヨウセイ ハイセンガン ノ 1レイ
|
Title Alternative | A case of anaplastic lymphoma kinase-positive non-small cell lung cancer with a poor performance status successfully treated with crizotinib
|
Author |
Kajita, Keisuke
The Post-graduate Education Center, Tokushima University Hospital
Sato, Seidai
Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Toyoda, Yuko
Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital
KAKEN Search Researchers
Sakaguchi, Satoshi
Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital
Tezuka, Toshifumi
Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital
KAKEN Search Researchers
Goto, Hisatsugu
Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital
KAKEN Search Researchers
Hanibuchi, Masaki
Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Nishioka, Yasuhiko
Department of Respiratory Medicine and Rheumatology, Tokushima University Hospital
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
|
Keywords | crizotinib
anaplastic lymphoma kinase
non-small cell lung cancer
performance status
|
Content Type |
Journal Article
|
Description | A 27-year-old female was referred to our hospital for further examination of hoarseness, cough, and hemoptysis. Positron emission tomography-computed tomography revealed FDG accumulation in a huge mass in the left lower lobe, lymph nodes in the hilum, mediastinum and right cervical lesion left scapula and vertebral body. Further examination yielded the diagnosis of primary lung adenocarcinoma (cT2aN3M1b : Stage IV) harboring the anaplastic lymphoma kinase (ALK) fusion oncogene. Although her general condition was getting worse due to rapid increase of the pleural effusion, crizotinib promptly diminish the pleural effusion and ameliorated the patient’s condition. The adverse events of crizotinib, such as nausea, vomiting and visual disturbance, were generally mild and well tolerable during treatment. These findings suggest that crizotinib is a promising candidate for ALK-positive non-small cell lung cancer patients even with poor performances.
|
Journal Title |
四国医学雑誌
|
ISSN | 00373699
|
NCID | AN00102041
|
Publisher | 徳島医学会
|
Volume | 71
|
Issue | 5-6
|
Start Page | 141
|
End Page | 148
|
Sort Key | 141
|
Published Date | 2015-12-25
|
EDB ID | |
FullText File | |
language |
jpn
|
TextVersion |
Publisher
|
departments |
University Hospital
Medical Sciences
|